Military families with TRICARE can now access FDA-cleared TMS depression treatment at Brain Treatment Center locations ...

Patients with major depressive disorder, including those who have not responded to first-line antidepressants, may benefit from short-term nitrous oxide treatment, a major meta-analysis led by the ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar depression. Clinical trials showed significant symptom improvement and potential ...

Major depressive disorder has been making headlines recently, but many of us don't actually know much about the condition.

Despite decades of advances in mental health care, depression remains one of the world's most disabling conditions. Many ...

The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults. This approval marks ...

Major Depressive Disorder (MDD) is a leading cause of global disability, and pharmacological intervention remains a cornerstone of its management. First-line agents typically comprise selective ...

The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major ...

The Food and Drug Administration (FDA) has cleared Proliv™Rx, an at-home neuromodulation therapy, for use as adjunctive treatment for adults with major depressive disorder (MDD) who have failed to ...

Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved ...

Researchers found that 8.3% of US adults had at least one major depressive episode. In adolescents, the rate was 20.1%, with 29.2% of female adolescents reporting a major depressive episode. Major ...

Certain things in life can trigger depressive episodes when you have MDD. Find out what to watch for, and what to do when it ...